UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment of Rocky Mountain spotted fever

Author
Daniel J Sexton, MD
Section Editor
Stephen B Calderwood, MD
Deputy Editor
Jennifer Mitty, MD, MPH

INTRODUCTION

Rocky Mountain spotted fever (RMSF) is a potentially lethal, but usually curable, tick-borne disease. It occurs throughout the United States, Canada, Mexico, Central America, and in parts of South America. The etiologic agent, Rickettsia rickettsii, is a gram-negative, obligate intracellular bacterium that causes a wide spectrum of clinical disease from mild to fulminant infection. Mortality from RMSF declined markedly in the last decade from 2.2 percent in 2000 to 0.3 percent in 2007, and has been essentially unchanged since that time [1,2].

The treatment of RMSF will be reviewed here. The basic biology of R. rickettsii, and the epidemiology, clinical manifestations, and diagnosis of RMSF are discussed separately. (See "Biology of Rickettsia rickettsii infection" and "Clinical manifestations and diagnosis of Rocky Mountain spotted fever".)

OVERVIEW

A diagnosis of Rocky Mountain spotted fever (RMSF) should be considered in individuals who present with fever, headache, and constitutional symptoms in the spring and summer months if:

They are from an endemic area (see "Clinical manifestations and diagnosis of Rocky Mountain spotted fever", section on 'Epidemiology')

and

                

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Aug 31 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Openshaw JJ, Swerdlow DL, Krebs JW, et al. Rocky mountain spotted fever in the United States, 2000-2007: interpreting contemporary increases in incidence. Am J Trop Med Hyg 2010; 83:174.
  2. http://www.cdc.gov/rmsf/stats/.
  3. Holman RC, Paddock CD, Curns AT, et al. Analysis of risk factors for fatal Rocky Mountain Spotted Fever: evidence for superiority of tetracyclines for therapy. J Infect Dis 2001; 184:1437.
  4. Walker DH. Rocky Mountain spotted fever: a seasonal alert. Clin Infect Dis 1995; 20:1111.
  5. Walker DH, Kirkman HN. Rocky Mountain spotted fever and deficiency in glucose-6-phosphate dehydrogenase. J Infect Dis 1980; 142:771.
  6. Centers for Disease Control and Prevention (CDC). Consequences of delayed diagnosis of Rocky Mountain spotted fever in children--West Virginia, Michigan, Tennessee, and Oklahoma, May-July 2000. MMWR Morb Mortal Wkly Rep 2000; 49:885.
  7. Marin-Garcia J, Gooch WM 3rd, Coury DL. Cardiac manifestations of Rocky Mountain spotted fever. Pediatrics 1981; 67:358.
  8. Rydkina E, Sahni A, Baggs RB, et al. Infection of human endothelial cells with spotted Fever group rickettsiae stimulates cyclooxygenase 2 expression and release of vasoactive prostaglandins. Infect Immun 2006; 74:5067.
  9. Kirkland KB, Wilkinson WE, Sexton DJ. Therapeutic delay and mortality in cases of Rocky Mountain spotted fever. Clin Infect Dis 1995; 20:1118.
  10. Regan JJ, Traeger MS, Humpherys D, et al. Risk factors for fatal outcome from rocky mountain spotted Fever in a highly endemic area-Arizona, 2002-2011. Clin Infect Dis 2015; 60:1659.
  11. O'Reilly M, Paddock C, Elchos B, et al. Physician knowledge of the diagnosis and management of Rocky Mountain spotted fever: Mississippi, 2002. Ann N Y Acad Sci 2003; 990:295.
  12. American Academy of Pediatrics. Rocky Mountain Spotted Fever. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK. (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012.
  13. Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55:1.
  14. Cunha BA. Clinical features of Rocky Mountain spotted fever. Lancet Infect Dis 2008; 8:143.
  15. Lochary ME, Lockhart PB, Williams WT Jr. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J 1998; 17:429.
  16. Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr 2015.
  17. DuPont HL, Hornick RB, Dawkins AT, et al. Rocky Mountain spotted fever: a comparative study of the active immunity induced by inactivated and viable pathogenic Rickettsia rickettsii. J Infect Dis 1973; 128:340.
  18. DuPont HL, Hornick RB, Weiss CF, et al. Evaluation of chloramphenicol acid succinate therapy of induced typhoid fever and rocky mountain spotted fever. N Engl J Med 1970; 282:53.
  19. Breitschwerdt EB, Davidson MG, Aucoin DP, et al. Efficacy of chloramphenicol, enrofloxacin, and tetracycline for treatment of experimental Rocky Mountain spotted fever in dogs. Antimicrob Agents Chemother 1991; 35:2375.
  20. American Academy of Pediatrics (AAP). Red Book: 2012 Report of the Committee on Infectious Diseases, 29, Pickering LK, Baker CJ, Kimberlin DW, Long SS. (Eds), American Academy of Pediatrics, Elk Grove, IL 2012.
  21. Wiest DB, Cochran JB, Tecklenburg FW. Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess. J Pediatr Pharmacol Ther 2012; 17:182.
  22. Dalton MJ, Clarke MJ, Holman RC, et al. National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 1995; 52:405.
  23. Archibald LK, Sexton DJ. Long-term sequelae of Rocky Mountain spotted fever. Clin Infect Dis 1995; 20:1122.
  24. Hayes SF, Burgdorfer W. Reactivation of Rickettsia rickettsii in Dermacentor andersoni ticks: an ultrastructural analysis. Infect Immun 1982; 37:779.
  25. Pretzman C, Daugherty N, Poetter K, Ralph D. The distribution and dynamics of Rickettsia in the tick population of Ohio. Ann N Y Acad Sci 1990; 590:227.